Paroxysmal Nocturnal Hemoglobinuria — Hemolysis, Thrombosis & Complement Inhibition

Key Points

• PNH is an acquired PIGA-mutant clonal stem-cell disorder causing deficiency of GPI-anchored complement regulators.
• Flow cytometry, not the sucrose-lysis or Ham test, is the modern diagnostic standard.
• LDH elevation, low haptoglobin, hemoglobinuria, and a negative DAT support intravascular hemolysis.
• Unusual-site thrombosis is a major diagnostic clue and a leading cause of morbidity.
• Small PNH clones in aplastic anemia do not automatically require complement inhibitor therapy.
• C5 inhibition markedly reduces intravascular hemolysis and thrombosis risk.
• Persistent anemia on C5 blockade may reflect extravascular hemolysis or marrow failure rather than treatment failure alone.
• Meningococcal infection risk remains clinically important despite vaccination.

Algorithm

1. Confirm hemolysis with CBC, reticulocytes, LDH, bilirubin, haptoglobin, urinalysis, and DAT.
2. Review for thrombosis, abdominal symptoms, marrow-failure features, transfusion history, and aplastic anemia/MDS context.
3. Order high-sensitivity flow cytometry on granulocytes and monocytes with FLAER/GPI-linked markers.
4. Quantify clone size and classify the clinical phenotype as subclinical clone, classical hemolytic PNH, or PNH with marrow failure.
5. Evaluate any focal symptoms urgently for thrombosis, including abdominal, cerebral, or hepatic venous thrombosis.
6. Start complement inhibition when clinically significant hemolysis, symptoms, transfusion need, thrombosis, or organ complications justify treatment.
7. Provide meningococcal and other indicated vaccination and infection-prevention counseling before or at urgent initiation.
8. If anemia persists, distinguish breakthrough hemolysis, extravascular hemolysis, iron deficiency, bleeding, renal disease, and marrow failure.

Clinical Synopsis & Reasoning

PNH should be suspected when otherwise unexplained Coombs-negative intravascular hemolysis occurs with one or more of the following: unusual-site venous thrombosis, abdominal pain, dysphagia, erectile dysfunction, pancytopenia, aplastic anemia, or episodic dark urine. The name is misleading because hemolysis is not restricted to nighttime. The disease begins with an acquired somatic PIGA mutation in a hematopoietic stem cell. Loss of glycosylphosphatidylinositol anchors prevents normal surface expression of complement-regulatory proteins, especially CD55 and CD59, leaving red cells vulnerable to complement-mediated destruction.

The laboratory pattern is one of intravascular hemolysis: elevated LDH, low haptoglobin, indirect hyperbilirubinemia, reticulocytosis when marrow reserve is adequate, and hemoglobinuria. Direct antiglobulin testing is generally negative. Cytopenias may reflect associated bone marrow failure rather than hemolysis alone. PNH is strongly linked to aplastic anemia and can coexist with myelodysplastic syndromes. Thrombosis is the most dangerous complication and often involves hepatic, portal, mesenteric, cerebral, or other atypical venous beds, although conventional DVT/PE also occurs.

The diagnostic test is high-sensitivity flow cytometry showing a population deficient in GPI-linked proteins. Modern assays use granulocytes and monocytes because transfusion and hemolysis can distort the apparent red-cell clone size. FLAER binding plus markers such as CD24, CD14, CD55, and CD59 helps quantify the clone. Bone marrow biopsy is not required simply to prove PNH, but it is important when cytopenias suggest marrow failure, aplastic anemia, MDS, or another clonal disorder.

The key reasoning distinction is between a small incidental PNH clone and clinically significant PNH. Small clones are common in aplastic anemia and do not automatically require complement inhibition. Treatment decisions depend on active hemolysis, symptoms, transfusion requirement, thrombosis, organ complications, and marrow function rather than clone size alone. Another common error is to treat anemia as purely hemolytic when marrow failure is the dominant problem.

Treatment Strategy & Disposition

Complement inhibition has transformed PNH management. C5 inhibitors such as eculizumab and ravulizumab suppress terminal complement-mediated intravascular hemolysis, reduce transfusion requirements, improve symptoms, and markedly lower thrombosis risk. Proximal complement inhibitors, including C3 or factor B-directed therapies in approved settings, can improve control of both intravascular and extravascular hemolysis in selected patients. Choice among agents depends on prior therapy, residual anemia mechanism, dosing preference, access, comorbidity, and regulatory indication.

Vaccination against encapsulated organisms, especially meningococcus, is essential before complement blockade when time permits because terminal complement inhibition increases susceptibility to invasive Neisseria infection. Vaccination lowers but does not eliminate risk. Patients need explicit fever/sepsis instructions and may require antimicrobial prophylaxis according to product labeling and local guidance.

Acute thrombosis is treated with therapeutic anticoagulation plus prompt complement inhibition if not already receiving it, unless a specific contraindication exists. Complement inhibition is not a substitute for acute anticoagulation. Transfusion support, folate replacement, and iron assessment are used when indicated. Allogeneic stem-cell transplantation is the only curative treatment for the underlying clone but is generally reserved for severe associated marrow failure, refractory disease, or another transplant indication because complement inhibitors provide excellent disease control for many patients.

If anemia persists despite apparent complement control, determine the mechanism before switching therapy. Possibilities include extravascular hemolysis from C3 opsonization, breakthrough intravascular hemolysis, iron deficiency from chronic hemoglobinuria, renal disease, bleeding, or bone marrow failure. Disposition is driven by thrombosis, severe symptomatic anemia, renal injury, hemolytic crisis, infection during complement inhibition, or marrow-failure complications.

Epidemiology / Risk Factors

• PNH is rare and often diagnosed in young or middle-aged adults, though it can occur at any age.
• PNH clones are enriched in patients with aplastic anemia.
• Thrombosis can occur at conventional or unusual venous sites.
• Clinical severity varies from asymptomatic small clones to life-threatening hemolysis and thrombosis.

Investigations

Persistent Anemia on Complement Therapy

Pharmacology

Prognosis / Complications

• Modern complement inhibition has substantially improved survival and quality of life.
• Thrombosis risk falls markedly with effective complement blockade but is not completely eliminated.
• Outcome is strongly influenced by associated bone marrow failure.
• Breakthrough hemolysis and residual anemia are manageable when the mechanism is correctly identified.

Patient Education / Counseling

• Explain that PNH is acquired rather than inherited in the usual sense.
• Teach patients receiving complement inhibitors to seek urgent care for fever, severe headache, neck stiffness, or sepsis symptoms.
• Review thrombosis symptoms, including new abdominal pain, neurologic symptoms, chest pain, or unilateral swelling.
• Discuss the purpose of vaccinations and why infection risk persists despite vaccination.
• Explain that persistent anemia may have several causes and should not lead to unplanned treatment changes without evaluation.

Notes

PNH is a model disease for mechanism-based treatment. The diagnostic question is not merely “is hemolysis present?” but “is complement-mediated clonal hemolysis present, and is it clinically important enough to justify targeted therapy?” Flow cytometry establishes the clone; the clinical phenotype establishes what to do about it.

The most testable trap is unusual-site thrombosis with Coombs-negative hemolysis. The most important management trap is assuming that every low hemoglobin value in a treated patient represents uncontrolled intravascular hemolysis. LDH, reticulocytes, iron studies, marrow reserve, and the pattern of complement inhibition should be interpreted together.

References

1. Panse JP, et al. Paroxysmal Nocturnal Hemoglobinuria, Pathophysiology, Diagnostics, and Treatment. 2024. — Link
2. Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood. 2021. — Link
3. Shi JJ, et al. Current landscape of PNH in the era of complement inhibitors. 2024. — Link